RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Newron Pharmaceuticals SpA Stock

Newron Pharmaceuticals SpA Equity 2024

Newron Pharmaceuticals SpA Equity

-29.91 M EUR

Ticker

NWRN.SW

ISIN

IT0004147952

WKN

A0LF18

In 2024, Newron Pharmaceuticals SpA's equity was -29.91 M EUR, a 113.17% increase from the -14.03 M EUR equity in the previous year.

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Newron Pharmaceuticals SpA's Equity

Newron Pharmaceuticals SpA's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Newron Pharmaceuticals SpA's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Newron Pharmaceuticals SpA's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Newron Pharmaceuticals SpA's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Newron Pharmaceuticals SpA’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

What is the equity of Newron Pharmaceuticals SpA this year?

Newron Pharmaceuticals SpA has equity of -29.91 M EUR this year.

What was the equity of Newron Pharmaceuticals SpA compared to the previous year?

The equity of Newron Pharmaceuticals SpA has increased/decreased by 113.17% increased compared to the previous year.

What impact does a high equity have on investors of Newron Pharmaceuticals SpA?

A high equity is advantageous for investors of Newron Pharmaceuticals SpA as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Newron Pharmaceuticals SpA?

A low equity can be a risk for investors of Newron Pharmaceuticals SpA, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Newron Pharmaceuticals SpA affect the company?

An increase in equity of Newron Pharmaceuticals SpA can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Newron Pharmaceuticals SpA affect the company?

A reduction in equity of Newron Pharmaceuticals SpA can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Newron Pharmaceuticals SpA?

Some factors that can affect the equity of Newron Pharmaceuticals SpA include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Newron Pharmaceuticals SpA so important for investors?

The equity of Newron Pharmaceuticals SpA is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Newron Pharmaceuticals SpA take to change the equity?

To change equity, Newron Pharmaceuticals SpA can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 12/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of Newron Pharmaceuticals SpA in the year 2023?

In the year 2023, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Newron Pharmaceuticals SpA

Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.